Back to today’s briefing

Story perspectives

Paxlovid Shows Limited Impact on Senior COVID Outcomes

2/21/2025

47 4

Summary

Story summary

A comprehensive study involving 1.6 million vaccinated seniors revealed that Paxlovid offers little to no reduction in COVID-19 hospitalizations or deaths. Despite a surge in prescriptions for seniors over 70, their outcomes mirrored those of younger patients with restricted access. Researchers are calling for more trials to evaluate Paxlovid's true effectiveness in high-risk groups, especially considering its hefty price tag of $1,650.

1 of 1

Story summary

A comprehensive study involving 1.6 million vaccinated seniors revealed that Paxlovid offers little to no reduction in COVID-19 hospitalizations or deaths. Despite a surge in prescriptions for seniors over 70, their outcomes mirrored those of younger patients with restricted access. Researchers are calling for more trials to evaluate Paxlovid's true effectiveness in high-risk groups, especially considering its hefty price tag of $1,650.